Evaluation of The Connection Between the Intensity of Non-Alcoholic Fatty Liver Disease (Nafld) And Respiratory Performance Among a Cohort of Individuals Gathered from The Adiwaniyah Region, Iraq: A Cross-Sectional Exploration
DOI:
https://doi.org/10.52783/jns.v14.1974Keywords:
non-alcoholic fatty liver disease, pulmonary functionAbstract
Background: Non-alcoholic fatty liver disease (NAFLD) stands as a prevalent culprit of chronic liver ailments across the globe. In the realm of NASH, the accumulation of fat in the liver is intertwined with inflammatory responses and cell death, potentially paving the way to fibrosis and cirrhosis. The delicate balance of pulmonary function can be swayed by a myriad of inherent (age, sex, ethnicity) and external (air pollution, smoking, biomass) influences. Moreover, its capability is compromised in diseases that affect areas beyond the lungs, such as cardiovascular disorders and chronic kidney issues. Notably, diminished pulmonary function has also been linked to the presence of nonalcoholic fatty liver disease (NAFLD).
Aim of the study: The aim of this study is to assess the severity of non-alcoholic fatty liver disease (NAFLD) in a sample of Iraqi patients using fibrsocan and correlate the severity to pulmonary function.
Patients and methods: The present investigation is a cross-sectional design that encompassed 124 individuals exhibiting clinical, laboratory, and imaging signs indicative of NAFLD, all of whom were enlisted from the gastroenterology hub at Al-Diwaniyah Teaching Hospital in Al-Diwaniyah, Iraq, during the timeframe spanning from February 2023 to April 2024. A Fibro scan (Fibroscan 530 compact, Echosense, Paris, France) was employed, with a skilled gastroenterologist overseeing the assessment of liver fibrosis and steatosis. For every participant enrolled in the research, spirometry was conducted utilizing the Cardio Touch - 3000 (Korea). The subsequent parameters were recorded: Forced Vital Capacity (FVC) and Forced Expiratory Volume in the first second (FEV1).
Results: The patients were categorized as follows: 26 individuals exhibited Normal (Fibrosis score 0), representing 21.0 %; 44 individuals showed Mild (Fibrosis score 1), comprising 35.5 %; 23 individuals were classified as Moderate (Fibrosis score 2), accounting for 18.5 %, while 31 individuals fell into the Severe category (Fibrosis score 3), making up 25.0 %. The interplay between pulmonary function tests and non-alcoholic fatty liver disease (NAFLD) was assessed according to fibroscan outcomes, revealing that 90 patients demonstrated normal function, while 34 patients exhibited a restrictive pattern, with a notable correlation between the escalating severity of liver fibrosis and the prevalence of restrictive patterns among patients (p = 0.003).
Conclusion: A significant proportion of patients with NAFLD have in addition impaired pulmonary function mostly in the form of restrictive changes and these changes are more frequently seen with increasing degree of liver fibrosis as indicated by fibroscan technique.
Downloads
Metrics
References
Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022 Mar 14;22(1):63. doi: 10.1186/s12902-022-00980-1. PMID: 35287643; PMCID: PMC8919523.
Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 2015;13(12):2062–2070.
Machado MV, Diehl AM. Pathogenesis of nonalcoholic Steatohepatitis. Gastroenterology. 2016;150(8):1769–1777.
Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2(2):199–210.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (Baltimore, Md) 2004;40(6):1387–1395.
Ozercan AM, Ozkan H. Vibration-controlled Transient Elastography in NAFLD: Review Study. Euroasian J Hepatogastroenterol. 2022 Jul;12(Suppl 1):S41-S45. doi: 10.5005/jp-journals-10018-1365. PMID: 36466098; PMCID: PMC9681576.
Yoneda M, Fujita K, Inamori M, et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007;56(9):1330–1331. doi: 10.1136/gut.2007.126417.
Talaminos Barroso A, Marquez Martin E, Roa Romero LM, Ortega Ruiz F. Factors Affecting Lung Function: A Review of the Literature. Archivos de bronconeumologia. 2018;54(6):327-332.
Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012;10(6):646-650.
Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2014;59(3):1174-1197.
Mantovani A, Lonardo A, Vinco G, et al. Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. Diabetes & metabolism. 2019.
Peng TC, Kao TW, Wu LW, et al. Association Between Pulmonary Function and Nonalcoholic Fatty Liver Disease in the NHANES III Study. Medicine. 2015;94(21):e907.
Jung DH, Shim JY, Lee HR, Moon BS, Park BJ, Lee YJ. Relationship between nonalcoholic fatty liver disease and pulmonary function. Internal medicine journal. 2012;42(5):541-546.
Lee CH, Choi SH, Chung GE, Park B, Kwak MS. Nonalcoholic fatty liver disease is associated with decreased lung function. Liver international : official journal of the International Association for the Study of the Liver. 2018;38(11):2091-2100.
Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. American journal of respiratory and critical care medicine. 2009;179(6):509-516.
Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung function with insulin resistance and Type 2 diabetes: findings from the British Women's Heart and Health Study. Diabetologia. 2004;47(2):195-203.
Baines KJ, Backer V, Gibson PG, Powel H, Porsbjerg CM. Impaired lung function is associated with systemic inflammation and macrophage activation. The European respiratory journal. 2015;45(2):557-559.
Liu XC, Huang Y, Lo K, Huang YQ, Chen JY, Feng YQ. Quotient of Waist Circumference and Body Mass Index: A Valuable Indicator for the High-Risk Phenotype of Obesity. Front Endocrinol (Lausanne). 2021 May 31;12:697437. doi: 10.3389/fendo.2021.697437. PMID: 34135867; PMCID: PMC8202120.
Kamali, L., Adibi, A., Ebrahimian, S., Jafari, F., & Sharifi, M. (2019). Diagnostic Performance of Ultrasonography in Detecting Fatty Liver Disease in Comparison with Fibroscan in People Suspected of Fatty Liver. Advanced biomedical research, 8, 69.
Principles of Anatomy and Physiology 16th Editionby Gerard J. Tortora , Bryan H. Derrickson 2020)
Hankinson, J. L., Odencrantz, J. R., & Fedan, K. B. (1999). Spirometric reference values from a sample of the general U.S. population. American journal of respiratory and critical care medicine, 159(1), 179–187.
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–968
Salmi, A., di Filippo, L., Ferrari, C., Frara, S., & Giustina, A. (2022). Ultrasound and FibroScan® Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis. Endocrine, 78(2), 262–269. https://doi.org/10.1007/s12020-022-03157-x
Yilmaz, Y., Ergelen, R., Akin, H., & Imeryuz, N. (2013). Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. European journal of gastroenterology & hepatology, 25(11), 1330–1334. https://doi.org/10.1097/MEG.0b013e3283623a16
Siddiqui, M. S., Vuppalanchi, R., Van Natta, M. L., Hallinan, E., Kowdley, K. V., Abdelmalek, M., Neuschwander-Tetri, B. A., Loomba, R., Dasarathy, S., Brandman, D., Doo, E., Tonascia, J. A., Kleiner, D. E., Chalasani, N., Sanyal, A. J., & NASH Clinical Research Network (2019). Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 17(1), 156–163.e2. https://doi.org/10.1016/j.cgh.2018.04.043
Aykut, U. E., Akyuz, U., Yesil, A., Eren, F., Gerin, F., Ergelen, R., Celikel, C. A., & Yilmaz, Y. (2014). A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scandinavian journal of gastroenterology, 49(11), 1343–1348. https://doi.org/10.3109/00365521.2014.958099
Mantovani, A., Byrne, C. D., Bonora, E., & Targher, G. (2018). Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes care, 41(2), 372–382. https://doi.org/10.2337/dc17-1902
Qin, L., Zhang, W., Yang, Z., Niu, Y., Li, X., Lu, S., Xing, Y., Lin, N., Zhang, H., Ning, G., Fan, J., & Su, Q. (2017). Impaired lung function is associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in middle-aged and elderly Chinese. BMC endocrine disorders, 17(1), 18. https://doi.org/10.1186/s12902-017-0168-4
Moon, S. W., Kim, S. Y., Jung, J. Y., Kang, Y. A., Park, M. S., Kim, Y. S., Chang, J., Ro, J. S., Lee, Y. H., & Lee, S. H. (2018). Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007-2010. International journal of chronic obstructive pulmonary disease, 13, 2603–2611. https://doi.org/10.2147/COPD.S166902
Lee, C. H., Choi, S. H., Chung, G. E., Park, B., & Kwak, M. S. (2018). Nonalcoholic fatty liver disease is associated with decreased lung function. Liver international : official journal of the International Association for the Study of the Liver, 38(11), 2091–2100. https://doi.org/10.1111/liv.13860
Song, J. U., Jang, Y., Lim, S. Y., Ryu, S., Song, W. J., Byrne, C. D., & Sung, K. C. (2019). Decreased lung function is associated with risk of developing non-alcoholic fatty liver disease: A longitudinal cohort study. PloS one, 14(1), e0208736. https://doi.org/10.1371/journal.pone.0208736
Kim S.Y., Han K.D., Yoon H.K., Kim S.W., An T. (2016). The relationship between nonalcoholic fatty liver disease and pulmonary function: KNHANES (Korean national health and nutrition examination survey 2008–2011)The relationship between nonalcoholic fatty liver disease and pulmonary function: KNHANES (Korean national health and nutrition examination survey 2008–2011). European Respiratory Journal 2016 48: PA3916; DOI: 10.1183/13993003.congress-2016.PA3916
Shen, J., Wang, Y., Zhou, S., Tang, M., Li, M., Han, R., Wang, R. (2023). Lung function and nonalcoholic fatty liver disease: a Mendelian randomization study. Archives of Medical Science. https://doi.org/10.5114/aoms/168475
Lee, H. W., Lee, D. H., Lee, J. K., Lee, S., Koo, B. K., Joo, S. K., Heo, E. Y., Jung, Y. J., Kim, W., & Kim, D. K. (2020). Pulmonary function is associated with fibrosis severity in patients with biopsy-proven nonalcoholic fatty liver disease. Liver international: official journal of the International Association for the Study of the Liver, 40(12), 3008–3017. https://doi.org/10.1111/liv.14626
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
